Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil.
Jansa P, Kopeć G, Torbicki A, Sadushi-Kolici R, Campean IA, Halank M, Simkova I, Steringer-Mascherbauer R, Salobir B, Klepetko W, Lindner J, Lang IM. Jansa P, et al. Among authors: halank m. Pulm Circ. 2023 Aug 21;13(3):e12274. doi: 10.1002/pul2.12274. eCollection 2023 Jul. Pulm Circ. 2023. PMID: 37609358 Free PMC article.
Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension.
Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, Meyer FJ, Karger G, Buss J, Juenger J, Holzapfel N, Opitz C, Winkler J, Herth FF, Wilkens H, Katus HA, Olschewski H, Grünig E. Mereles D, et al. Among authors: halank m. Circulation. 2006 Oct 3;114(14):1482-9. doi: 10.1161/CIRCULATIONAHA.106.618397. Epub 2006 Sep 18. Circulation. 2006. PMID: 16982941 Clinical Trial.
Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction : Study protocol for a randomized controlled trial.
Mascherbauer J, Grünig E, Halank M, Hohenforst-Schmidt W, Kammerlander AA, Pretsch I, Steringer-Mascherbauer R, Ulrich S, Lang IM, Wargenau M, Frey R, Bonderman D. Mascherbauer J, et al. Among authors: halank m. Wien Klin Wochenschr. 2016 Dec;128(23-24):882-889. doi: 10.1007/s00508-016-1068-8. Epub 2016 Sep 2. Wien Klin Wochenschr. 2016. PMID: 27590259 Free PMC article. Clinical Trial.
Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.
McLaughlin VV, Jansa P, Nielsen-Kudsk JE, Halank M, Simonneau G, Grünig E, Ulrich S, Rosenkranz S, Gómez Sánchez MA, Pulido T, Pepke-Zaba J, Barberá JA, Hoeper MM, Vachiéry JL, Lang I, Carvalho F, Meier C, Mueller K, Nikkho S, D'Armini AM. McLaughlin VV, et al. Among authors: halank m. BMC Pulm Med. 2017 Dec 28;17(1):216. doi: 10.1186/s12890-017-0563-7. BMC Pulm Med. 2017. PMID: 29282032 Free PMC article. Clinical Trial.
Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial.
Sadushi-Kolici R, Jansa P, Kopec G, Torbicki A, Skoro-Sajer N, Campean IA, Halank M, Simkova I, Karlocai K, Steringer-Mascherbauer R, Samarzija M, Salobir B, Klepetko W, Lindner J, Lang IM. Sadushi-Kolici R, et al. Among authors: halank m. Lancet Respir Med. 2019 Mar;7(3):239-248. doi: 10.1016/S2213-2600(18)30367-9. Epub 2018 Nov 23. Lancet Respir Med. 2019. PMID: 30477763 Clinical Trial.
[Hemodynamic Definition of Pulmonary Hypertension: Commentary on the Proposed Change by the 6th World Symposium on Pulmonary Hypertension].
Rosenkranz S, Diller GP, Dumitrescu D, Ewert R, Ghofrani HA, Grünig E, Halank M, Held M, Kaemmerer H, Klose H, Kovacs G, Konstantinides S, Lang IM, Lange TJ, Leuchte H, Mayer E, Olschewski A, Olschewski H, Olsson KM, Opitz C, Schermuly RT, Seeger W, Wilkens H, Hoeper MM. Rosenkranz S, et al. Among authors: halank m. Dtsch Med Wochenschr. 2019 Sep;144(19):1367-1372. doi: 10.1055/a-0918-3772. Epub 2019 Jul 5. Dtsch Med Wochenschr. 2019. PMID: 31277079 Free article. German.
Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial.
White RJ, Jerjes-Sanchez C, Bohns Meyer GM, Pulido T, Sepulveda P, Wang KY, Grünig E, Hiremath S, Yu Z, Gangcheng Z, Yip WLJ, Zhang S, Khan A, Deng CQ, Grover R, Tapson VF; FREEDOM-EV Investigators. White RJ, et al. Am J Respir Crit Care Med. 2020 Mar 15;201(6):707-717. doi: 10.1164/rccm.201908-1640OC. Am J Respir Crit Care Med. 2020. PMID: 31765604 Free PMC article. Clinical Trial.
Mutually reinforcing effects of genetic variants and interferon-β 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patients.
Lerche M, Eichstaedt CA, Hinderhofer K, Grünig E, Tausche K, Ziemssen T, Halank M, Wirtz H, Seyfarth HJ. Lerche M, et al. Among authors: halank m. Pulm Circ. 2019 Nov 18;9(3):2045894019872192. doi: 10.1177/2045894019872192. eCollection 2019 Jul-Sep. Pulm Circ. 2019. PMID: 31798832 Free PMC article.
174 results